Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.51 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8188234 | 0.96 | KMT2A (0.65) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL2368807 | 0.87 | ALDH1A1 (0.67) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL13838083 | 0.87 | PRKCZ (0.61) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL3980970 | 0.86 | ALDH1A1 (0.65) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL26038507 | 0.86 | PRKCZ (0.69) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL8196570 | 0.86 | ALDH1A1 (0.62) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL13926187 | 0.84 | ALDH1A1 (0.70) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL2367950 | 0.84 | PRKCZ (0.63) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL2368512 | 0.84 | PRKCZ (0.68) | KMT2AALDH1A1MEN1PRKCZLMNA | |
| SCHEMBL13926190 | 0.84 | PRKCZ (0.51) | KMT2AALDH1A1MEN1PRKCZLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| WO-2020139803-A1 | BENZOTHIADIAZINE DERIVATIVES AND COMPOSITIONS COMPRISING THE SAME FOR TREATING DISORDERS MEDIATED BY ADENOSINE | DCB-USA LLC (US) | 2020-07-02 | — | — | WO | disclosed |
| CN-102803269-B | Thieno [2,3-B ] pyrimidinedione activators of AMPK and therapeutic uses thereof | POXEL (FR) | 2016-01-13 | — | — | CN | disclosed |
| WO-2015075051-A1 | ALLOSTERIC INHIBITORS OF ATYPICAL PROTEIN KINASES C | UNIVERSITAET DES SAARLANDES (DE) | 2015-05-28 | — | — | WO | disclosed |
| CN-1823071-B | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD | 2012-12-19 | — | — | CN | disclosed |
| WO-2012166891-A2 | MU-OPIOID RECEPTOR BINDING COMPOUNDS | ALGYNOMICS INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| CN-102803269-A | Thieno [2,3-B ] pyrimidinedione activators of AMPK and therapeutic uses thereof | POXEL | 2012-11-28 | — | — | CN | disclosed |
| US-7951806-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| CN-1823071-A | Thienopyrimidine derivatives as potassium channel inhibitors | XENTION DISCOVERY LTD (GB) | 2006-08-23 | — | — | CN | disclosed |
| US-4866065-A | ANTICONVULSANTS, ANXIOLYTIC AGENTS, HYPNOTICS, AND COGNITION ACTIVATORS | A/S FERROSAN (DK) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124620-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | KMT2A 3782/4885ALDH1A1 800/4885MEN1 582/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | KMT2A 3255/4885ALDH1A1 2378/4885MEN1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.